Journal ArticleDOI
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Stefan S. Bielack,Beate Kempf-Bielack,Günter Delling,G. Ulrich Exner,Silke Flege,Knut Helmke,Rainer Kotz,Mechthild Salzer-Kuntschik,M. Werner,Winfried Winkelmann,Andreas Zoubek,Heribert Jürgens,Kurt Winkler +12 more
Reads0
Chats0
TLDR
Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.Abstract:
PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival. The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions. RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis. Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%. Among the variables assessable at diagnosis, patient age (actuarial 10-y...read more
Citations
More filters
Journal ArticleDOI
Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells
TL;DR: Findings suggest that the inhibition of the p38 MAPK pathway may be attractive in overcoming cellular resistance against MIN, and MIN may have a beneficial adjuvant role in the DOX treatment.
Journal ArticleDOI
Long noncoding RNA NORAD regulates cancer cell proliferation and migration in human osteosarcoma by endogenously competing with miR-199a-3p.
TL;DR: The results of this study show that NORAD plays an important role in regulating cancer cell functions of osteosarcoma, possibly through endogenously competing with hsa‐miR‐199a‐3p.
Journal ArticleDOI
Osteosarcoma after allogeneic bone marrow transplantation. A report of four cases from the Cooperative Osteosarcoma Study Group (COSS)
Stefan S. Bielack,J S Rerin,Roswitha Dickerhoff,Dagmar Dilloo,Bernhard Kremens,A von Stackelberg,Josef Vormoor,Heribert Jürgens +7 more
TL;DR: Osteosarcoma should be included among the secondary malignancies that can arise following hematopoietic stem cell transplantation, and multi-modal therapy according to guidelines for de novo osteosarca can lead to long-term survival in selected patients.
Journal ArticleDOI
miR-17-5p promotes the growth of osteosarcoma in a BRCC2-dependent mechanism.
TL;DR: It is demonstrated that BRCC2 is a direct target of miR-17-5p and may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of osteosarcoma.
Journal Article
Extraskeletal osteosarcoma in Norway, between 1975 and 2009, and a brief review of the literature.
TL;DR: The relatively poor prognosis of ESOS may relate to both primary chemotherapy resistance and different biologic characteristics of these tumours as compared to conventional osteosarcoma.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
TL;DR: There is substantial under representation of patients 65 years of age or older in studies of treatment for cancer, and the reasons should be clarified, and policies adopted to correct this underrepresentation.